Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands The US president had put pressure on the pharmaceutical industry to make drugs cheaper for Americans The Guardian - UK · Aug 14, 2025
Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen. Benzinga · Aug 14, 2025
Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170% The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS). Euronews · Aug 14, 2025
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and… Benzinga · Aug 13, 2025
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results. Benzinga · Aug 13, 2025
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss. Benzinga · Aug 13, 2025
UK Government, Eli Lilly Partner To Target Obesity Health Gaps A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients. Benzinga · Aug 12, 2025
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me' On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc (NASDAQ:AFRM) is a buy. “It's at $72, it's going to $100,” he noted. Benzinga · Aug 12, 2025
Government partners with Mounjaro maker to tackle obesity The £85 million programme will looks at ways for patients to access services more easily. Evening Standard · Aug 12, 2025
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients. Benzinga · Aug 11, 2025
Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio? These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio? Benzinga · Aug 10, 2025
The Saturday Spread: Using the Neglected Methodology That Wall Street Refuses to Teach While understanding so-called ‘options math’ can provide interesting context and color, the real alpha generation comes from an entirely different framework. Barchart · Aug 9, 2025
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. MarketBeat · Aug 9, 2025
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. Benzinga · Aug 9, 2025
Benzinga · Aug 9, 2025 Trump's Gold Tariffs Shake Markets, Eli Lilly Plunges, Oil Dips On US-Russia Deal, Jobs Miss Fuels Recession Fears — This Week In Economy The past week has been a rollercoaster ride for the financial markets. From President Donald Trump‘s surprising tariffs on gold to Eli Lilly’s worst day in 25 years, the week was filled with unexpected turns. Let’s dive into the top stories that shaped the week.
Saving Advice · Aug 8, 2025 My Portfolio, Powered by AI: The Surprising Truth About Automated Investing When it comes to investing, research is everything. But let’s be honest, it can also be time-consuming and overwhelming, especially if you have never invested...
Benzinga · Aug 8, 2025 Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.
MarketBeat · Aug 8, 2025 Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.
Barchart · Aug 8, 2025 S&P Futures Gain as Investors Weigh Trump’s Fed Governor Pick; Gold Futures Jump on Tariff Report September S&P 500 E-Mini futures (ESU25) are trending up +0.32% this morning, capping a week dominated by tariff and geopolitical developments, as well as a wave of earnings, with investors weighing U.S. President Donald Trump’s efforts to tighten his grip on the Federal Reserve.
Benzinga · Aug 8, 2025 The Trade Desk, SoundHound AI, Eli Lilly, Block And CrowdStrike: Why These 5 Stocks Are On Investors' Radars Today The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70. Meanwhile, the SP 500 fell by 0.08% to 6,340, and the Dow Jones Industrial Average experienced a decline of 0.5% to settle at 43,968.64.
Barchart · Aug 7, 2025 Stocks Close Mixed after Higher Bond Yields and Tariff News The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. September E-mini S&P futures (ESU25 ) fell -0.04%, and September E-mini Nasdaq futures (NQU25...
Kiplinger · Aug 7, 2025 Stocks Swing Lower as Eli Lilly, Fortinet Spiral: Stock Market Today The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.
The Guardian - UK · Aug 7, 2025 Daily pill helps patients lose 12% of body weight in early trial Results of study suggest orforglipron could be a simpler, cheaper alternative to injections
Benzinga · Aug 7, 2025 Eli Lilly Co. Q2 FY2025 Earnings Transcript Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.
Benzinga · Aug 7, 2025 Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday? U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.